Maple Syrup Urine Disease – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Maple Syrup Urine Disease – Drugs In Development, 2024 report and make more profitable business decisions.
Maple Syrup Urine Disease is a rare inherited metabolic disease caused by a deficiency of an enzyme alpha-ketoacid dehydrogenase complex (BCKD) as a result accumulation of proteins harmful proteins or certain amino acids in blood and urine are found. Predominant in infants and older groups. Sweet-smelling urine, loss of appetite, anorexia, and breathing difficulties are common symptoms. If diagnosed in infant emergency treatment is initiated to prevent complications. Whole blood picture, genetic mutations on BCKDHA, BCKDHB. Dietary leucine restriction, liver transplantation, and non-pharmacological methods are low protein diet, preventive measures, and genetic counseling.
The Maple Syrup Urine Disease drugs in development market research report provide comprehensive information on the therapeutics under development for Maple Syrup Urine Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Maple Syrup Urine Disease and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Maple Syrup Urine Disease | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 10 molecules, with 10 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Maple Syrup Urine Disease therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Maple Syrup Urine Disease pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Maple Syrup Urine Disease treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
ASC Therapeutics IncCodexis Inc
Darling Therapeutics LLC
LyGenesis Inc
Moderna Inc
Ramino-Bio Ltd
Recordati Rare Diseases Inc
Relief Therapeutics Holding AG
Synlogic Inc
Zevra Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Maple Syrup Urine Disease reports